vs
CytomX Therapeutics, Inc.（CTMX）とSilvercrest Asset Management Group Inc.（SAMG）の財務データ比較。上の社名をクリックして会社を切り替えられます
Silvercrest Asset Management Group Inc.の直近四半期売上が大きい（$32.0M vs $18.7M、CytomX Therapeutics, Inc.の約1.7倍）。Silvercrest Asset Management Group Inc.の純利益率が高く（-0.4% vs -0.8%、差は0.4%）。Silvercrest Asset Management Group Inc.の前年同期比売上増加率が高い（-0.0% vs -25.7%）。Silvercrest Asset Management Group Inc.の直近四半期フリーキャッシュフローが多い（$15.0M vs $-15.8M）。過去8四半期でSilvercrest Asset Management Group Inc.の売上複合成長率が高い（2.7% vs -15.9%）
CytomX Therapeuticsは臨床段階のバイオテクノロジー企業で、革新的ながん免疫療法の開発を専門としています。独自のProbody技術プラットフォームを活用し、腫瘍微小環境でのみ活性化する標的療法を開発し、オフターゲット毒性を抑え、複数の固形がん向けパイプラインを展開し、大手製薬企業と提携して治療候補の開発を進めています。
CTMX vs SAMG — 直接比較
損益計算書 — Q2 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $18.7M | $32.0M |
| 純利益 | $-154.0K | $-120.0K |
| 粗利率 | — | — |
| 営業利益率 | -6.9% | -2.8% |
| 純利益率 | -0.8% | -0.4% |
| 売上前年比 | -25.7% | -0.0% |
| 純利益前年比 | 97.6% | -107.4% |
| EPS（希薄化後） | — | $0.02 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | — | $32.0M | ||
| Q3 25 | — | $31.3M | ||
| Q2 25 | $18.7M | $30.7M | ||
| Q1 25 | $50.9M | $31.4M | ||
| Q4 24 | $38.1M | $32.0M | ||
| Q3 24 | $33.4M | $30.4M | ||
| Q2 24 | $25.1M | $31.0M | ||
| Q1 24 | $41.5M | $30.3M |
| Q4 25 | — | $-120.0K | ||
| Q3 25 | — | $618.0K | ||
| Q2 25 | $-154.0K | $1.9M | ||
| Q1 25 | $23.5M | $2.5M | ||
| Q4 24 | $18.9M | $1.6M | ||
| Q3 24 | $5.7M | $2.3M | ||
| Q2 24 | $-6.5M | $2.7M | ||
| Q1 24 | $13.8M | $3.0M |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | -6.9% | 13.2% | ||
| Q1 25 | 44.4% | 15.4% | ||
| Q4 24 | 46.4% | 6.1% | ||
| Q3 24 | 12.3% | 14.6% | ||
| Q2 24 | -33.7% | 17.1% | ||
| Q1 24 | 28.1% | 19.5% |
| Q4 25 | — | -0.4% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | -0.8% | 6.3% | ||
| Q1 25 | 46.2% | 7.9% | ||
| Q4 24 | 49.6% | 5.1% | ||
| Q3 24 | 17.2% | 7.4% | ||
| Q2 24 | -26.0% | 8.6% | ||
| Q1 24 | 33.3% | 9.9% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $0.07 | ||
| Q2 25 | — | $0.21 | ||
| Q1 25 | — | $0.26 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | — | $0.24 | ||
| Q2 24 | — | $0.28 | ||
| Q1 24 | — | $0.32 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $49.0M | $44.1M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $119.9M | $50.3M |
| 総資産 | $175.1M | $166.6M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | — | $44.1M | ||
| Q3 25 | — | $36.1M | ||
| Q2 25 | $49.0M | $30.0M | ||
| Q1 25 | $47.6M | $36.3M | ||
| Q4 24 | $38.1M | $68.6M | ||
| Q3 24 | $40.6M | $58.1M | ||
| Q2 24 | $43.2M | $49.9M | ||
| Q1 24 | $36.2M | $39.7M |
| Q4 25 | — | $50.3M | ||
| Q3 25 | — | $58.9M | ||
| Q2 25 | $119.9M | $64.6M | ||
| Q1 25 | $25.0M | $80.0M | ||
| Q4 24 | $-456.0K | $80.7M | ||
| Q3 24 | $-23.5M | $84.6M | ||
| Q2 24 | $-31.2M | $85.3M | ||
| Q1 24 | $-31.7M | $83.9M |
| Q4 25 | — | $166.6M | ||
| Q3 25 | — | $157.6M | ||
| Q2 25 | $175.1M | $152.7M | ||
| Q1 25 | $98.5M | $159.9M | ||
| Q4 24 | $120.5M | $194.4M | ||
| Q3 24 | $139.0M | $184.2M | ||
| Q2 24 | $159.2M | $177.6M | ||
| Q1 24 | $184.7M | $170.2M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-15.8M | $18.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $-15.8M | $15.0M |
| FCFマージンFCF / 売上 | -84.6% | 46.9% |
| 設備投資強度設備投資 / 売上 | 0.1% | 11.4% |
| キャッシュ転換率営業CF / 純利益 | — | — |
| 直近12ヶ月FCF直近4四半期 | $-77.7M | $17.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | $-15.8M | $13.8M | ||
| Q1 25 | $-21.0M | $-24.7M | ||
| Q4 24 | $-19.9M | $21.6M | ||
| Q3 24 | $-20.7M | $13.3M | ||
| Q2 24 | $-19.5M | $16.0M | ||
| Q1 24 | $-26.0M | $-24.1M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | $-15.8M | $13.4M | ||
| Q1 25 | $-21.2M | $-25.1M | ||
| Q4 24 | $-20.0M | $19.9M | ||
| Q3 24 | $-20.7M | $12.9M | ||
| Q2 24 | $-19.6M | $15.6M | ||
| Q1 24 | $-26.2M | $-24.7M |
| Q4 25 | — | 46.9% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | -84.6% | 43.6% | ||
| Q1 25 | -41.6% | -80.0% | ||
| Q4 24 | -52.5% | 62.2% | ||
| Q3 24 | -62.1% | 42.4% | ||
| Q2 24 | -78.2% | 50.4% | ||
| Q1 24 | -63.1% | -81.6% |
| Q4 25 | — | 11.4% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.2% | 1.3% | ||
| Q4 24 | 0.2% | 5.3% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 0.3% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | -0.89× | -10.01× | ||
| Q4 24 | -1.05× | 13.34× | ||
| Q3 24 | -3.61× | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | -1.89× | -8.03× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
